Neuronetics, Inc.: directors' dealings · United States · SEC (Form 4)

About Neuronetics, Inc.

Neuronetics, Inc. (ticker: STIM) is a U.S.-based medical technology company listed on the NASDAQ market in the United States. The company focuses on the design, development, commercialization, and support of non-invasive neurohealth treatments, with a primary emphasis on mental health disorders. Headquartered in Malvern, Pennsylvania, Neuronetics is positioned as a commercial-stage, vertically integrated healthcare business that combines device sales, clinical services, and recurring revenue streams tied to treatment delivery and patient access. ([ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-reports-first-quarter-2026-financial-and-operating?utm_source=openai)) Neuronetics was founded in the late 2000s and built its business around its flagship product, NeuroStar Advanced Therapy, a transcranial magnetic stimulation (TMS) system used in office-based care settings. NeuroStar is FDA-cleared for adult patients with major depressive disorder who have not achieved satisfactory improvement from prior antidepressant medication in the current episode. That regulatory clearance is strategically important because it supports physician adoption, payer engagement, and broader clinical acceptance in a still-developing treatment category. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1227636/000110465926029004/stim-20251231x10k.htm?utm_source=openai)) The company’s operating model is centered on three main economic drivers: sales of NeuroStar systems, services and clinic-related revenue, and other revenues associated with system utilization and support. This hybrid model allows Neuronetics to participate both in the upfront sale of capital equipment and in the ongoing economics of therapy delivery. Recent company disclosures indicate that its clinic business has been a meaningful growth engine, while management has also highlighted improvements in operating cash flow and a stronger commercial cadence in the U.S. market. ([ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-reports-first-quarter-2026-financial-and-operating?utm_source=openai)) From a competitive perspective, Neuronetics is one of the better-known branded players in TMS for depression, operating in a market that remains underpenetrated relative to the size of the addressable patient population. The company has been strengthening its commercial footprint through partnerships designed to expand patient access and provider reach. A notable example is its three-year exclusive partnership with Elite DNA Behavioral Health, one of Florida’s largest and fastest-growing behavioral health networks, aimed at making NeuroStar the sole TMS device across that network’s sites. Neuronetics also expanded scale through the acquisition of Greenbrook TMS, which broadened its clinic footprint and increased exposure to recurring therapy revenue. ([ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-announces-three-year-exclusive-partnership-elite-dna/?utm_source=openai)) Geographically, Neuronetics remains heavily U.S.-focused, with the United States as its core commercial market and the main source of revenue. The company’s most recent updates underscore continued domestic execution: in the first quarter of 2026, Neuronetics reported revenue growth, higher U.S. clinic revenue, more NeuroStar systems shipped in the U.S., and improved operating cash outflow versus the prior year. For investors, the stock represents a specialized healthcare name on NASDAQ with exposure to reimbursement trends, clinical adoption, and the execution risk typical of a commercial-stage medtech company. ([ir.neuronetics.com](https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-reports-first-quarter-2026-financial-and-operating?utm_source=openai))